Loading...
XNAS
ANIP
Market cap1.39bUSD
Jul 30, Last price  
64.03USD
1D
-0.26%
1Q
-9.42%
Jan 2017
5.63%
IPO
-76.60%
Name

ANI Pharmaceuticals Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.26
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.92%
Rev. gr., 5y
24.36%
Revenues
614m
+26.20%
258,35114,438,621493,0543,780,8291,258,0542,474,237435,1602,300,73630,082,00055,970,00076,322,000128,622,000176,842,000201,576,000206,547,000208,475,000216,136,000316,385,000486,816,000614,376,000
Net income
-19m
L
-9,651,0362,791,273-7,584,435-17,425,178-47,527,768-46,196,216-51,608,504-27,717,739301,00028,747,00015,375,0003,934,000-1,076,00015,494,0006,094,000-22,548,000-42,603,000-47,896,00018,779,000-18,522,000
CFO
64m
-46.19%
-8,297,509-4,996,735739,992-15,535,932-18,430,910-40,097,506-47,870,103-25,283,020-5,484,00022,033,00017,264,00027,472,00039,419,00067,074,00045,631,00015,267,0003,322,000-31,203,000118,959,00064,017,000
Earnings
Aug 04, 2025

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
URL
https://www.anipharmaceuticals.com/
IPO date
May 04, 2000
Employees
600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
614,376
26.20%
486,816
53.87%
316,385
46.38%
Cost of revenue
44,581
215,799
161,103
Unusual Expense (Income)
NOPBT
569,795
271,017
155,282
NOPBT Margin
92.74%
55.67%
49.08%
Operating Taxes
(3,690)
1,093
(14,769)
Tax Rate
0.40%
NOPAT
573,485
269,924
170,051
Net income
(18,522)
-198.63%
18,779
-139.21%
(47,896)
12.42%
Dividends
(1,625)
(1,625)
(1,625)
Dividend yield
0.15%
0.16%
0.25%
Proceeds from repurchase of equity
(10,959)
75,568
(501)
BB yield
1.03%
-7.53%
0.08%
Debt
Debt current
9,172
2,411
850
Long-term debt
305,812
289,628
287,050
Deferred revenue
Other long-term liabilities
355,675
16,527
(44,924)
Net debt
163,816
70,918
230,913
Cash flow
Cash from operating activities
64,017
118,959
(31,203)
CAPEX
(8,868)
(16,455)
Cash from investing activities
(404,719)
(18,511)
(15,738)
Cash from financing activities
264,945
67,439
(5,126)
FCF
526,251
285,375
133,673
Balance
Cash
151,168
221,121
48,228
Long term investments
8,759
Excess cash
120,449
196,780
41,168
Stockholders' equity
(70,083)
(46,423)
(60,267)
Invested Capital
1,169,272
807,779
636,575
ROIC
58.01%
37.38%
25.49%
ROCE
51.84%
35.60%
23.61%
EV
Common stock shares outstanding
19,318
18,194
16,260
Price
55.28
0.25%
55.14
37.06%
40.23
-12.70%
Market cap
1,067,899
6.45%
1,003,217
53.36%
654,140
12.70%
EV
1,256,565
1,098,985
909,903
EBITDA
637,526
330,808
214,935
EV/EBITDA
1.97
3.32
4.23
Interest
17,602
26,940
28,052
Interest/NOPBT
3.09%
9.94%
18.07%